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Abstract
Purpose—3-Methylcrotonyl-CoA carboxylase deficiency (MCCD) is an autosomal recessive 
disorder of leucine catabolism that has a highly variable clinical phenotype, ranging from acute 
metabolic acidosis to nonspecific symptoms such as developmental delay, failure to thrive, 
hemiparesis, muscular hypotonia, and multiple sclerosis. Implementation of newborn screening for 
MCCD has resulted in broadening the range of phenotypic expression to include asymptomatic 
adults. The purpose of this study was to identify factors underlying the varying phenotypes of 
MCCD.
Methods—We performed exome sequencing on DNA from 33 cases and 108 healthy controls. 
We examined these data for associations between either MCC mutational status, genetic ancestry, 
or consanguinity and the absence or presence/specificity of clinical symptoms in MCCD cases.
Results—We determined that individuals with nonspecific clinical phenotypes are highly inbred 
compared with cases that are asymptomatic and healthy controls. For 5 of these 10 individuals, we 
discovered a homozygous damaging mutation in a disease gene that is likely to underlie their 
nonspecific clinical phenotypes previously attributed to MCCD.
Conclusion—Our study shows that nonspecific phenotypes attributed to MCCD are associated 
with consanguinity and are likely not due to mutations in the MCC enzyme but result from rare 
homozygous mutations in other disease genes.
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INTRODUCTION
3-Methylcrotonyl-CoA carboxylase (MCC) deficiency (MCCD) is a recessive disorder 
caused by homozygous or compound heterozygous mutations in either MCCC1 or MCCC2. 
Each encodes a subunit of MCC, a biotin-dependent enzyme in the catabolic pathway of 
leucine.1 Clinical expression of MCCD has highly heterogeneous clinical symptoms; some 
individuals present with developmental delay, intellectual disability, neonatal seizures, 
ketoacidosis, cerebral edema, coma, or early death, whereas others are asymptomatic into 
adulthood.2–5 Our previous studies have shown that the causative mutations are located 
throughout the entire coding and some intronic sequences of MCCC1 and MCCC2, resulting 
in a spectrum of genetic lesions including nonsynonymous, nonsense, splicing, and 
frameshift mutations. Approximately half of the individuals with MCCD are homozygous 
for the causative mutation, whereas the other half has compound heterozygous genotypes. 
Interestingly, neither the type of genetic lesion nor the status of homozygous or compound 
heterozygous mutation appears to be associated with severity of clinical symptoms.6
Although children with MCCD were previously identified during evaluation of 
developmental disability, metabolic disturbances, or Reye syndrome,7 newborn screening by 
tandem mass spectrometry (targeting 3-hydroxyisovalerylcarnitine as C5OH-carnitine)8 in 
the United States and a number of other countries around the world has resulted in greatly 
increased ascertainment of MCCD, with an estimated prevalence between 1:41,700 and 
1:84,700.9,10 Before its inclusion in newborn screening programs, there were only ~30 
reported cases of MCCD.11 Surprisingly, MCCD was found to be the third most common 
organic acid disorder detected in the newborn screening program in California10; however, 
results of a comparative analysis of case reports with newborn screening data suggest that 
less than 10% of affected individuals ever develop minor symptoms and less than 1 to 2% 
have a more severe outcome.11 When symptoms in an infant are ascertained through 
newborn screening, it is currently not possible to estimate clinical risk, and thus he/she is 
frequently administered lifelong treatment regimens including low-protein dietary 
modification and carnitine supplements. Because symptomatology is rarer than previously 
thought, prior to newborn screening programs, it is important to determine why some 
individuals show variable clinical symptoms and others do not. The risk–benefit balance of 
newborn screening is complicated because there are potential risks involved with too little 
intervention (not screening or not treating cases that will become symptomatic) or too much 
intervention (possibly resulting in unnecessary treatment, insurance implications, 
stigmatization, or promotion of anxiety in asymptomatic cases).
Recent reports have proposed that the attribution of nonspecific symptoms such as 
intellectual disability, attention deficit disorders, and fatigue to MCCD is questionable10,11 
and may be caused by genetic variation outside of MCCC1 and MCCC2.12 A number of 
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MCCD patients have been previously reported to have consanguineous parents,12 which is 
associated with a wide variety of health and physical defects attributable to increased 
numbers of deleterious recessive alleles in the homozygous state. However, using self-
reported family histories there was no significant association between parental 
consanguinity and the presence or absence of symptoms.12 Because of the importance of 
understanding the genetic components that underlie the diverse clinical manifestations of 
MCCD, in the present study we have used whole-exome sequencing data to directly 
investigate the role of genetic ancestry and consanguinity.
MATERIALS AND METHODS
Cohort selection
All samples were derived from remainders of specimens sent for clinical testing. Although 
many infants with MCCD that is ascertained through newborn screening appear to be 
healthy, it is not clear that they will remain asymptomatic. Accordingly, we analyzed 18 
asymptomatic mothers who were discovered to have MCCD only by detection of abnormal 
C5OH-carnitine in the newborn screening sample from their healthy babies in whom the 
acylcarnitine elevation resolved. With the exception of subject A16, who had been 
previously reported,6 all other samples from asymptomatic individuals in this study were 
leftover aliquots of de-identified samples from adult females referred to our laboratory for 
diagnostic enzyme assay with clinical history as indicated. Lymphocytes derived from these 
18 individuals were assayed and determined to have a very profound deficiency of MCC. 
Samples were also studied from 15 patients who were previously reported to be 
symptomatic,2–4,6,13–22 some of whom exhibited specific symptoms that are direct 
biochemical correlates of defective leucine catabolism,23 whereas others were reported to 
have a wide range of nonspecific symptoms (as outlined in Supplementary Table S1 online). 
Specific symptoms included ketoacidosis, hypoglycemia, hyperammonemia, coma, and 
plasma carnitine depletion with gross elevation of hydroxyisovaleryl-carnitine. Nonspecific 
symptoms, which are not directly related to leucine metabolism, included developmental 
delay, intellectual disability, seizures, hemiparesis, muscular hypotonia, and multiple 
sclerosis (Supplementary Table S1 online). We separated the MCCD cases into three 
groups, with group 1 containing 18 asymptomatic individuals, group 2 containing 5 
individuals manifesting specific symptoms, and group 3 containing 10 individuals 
manifesting only nonspecific symptoms. One hundred eight healthy individuals of 
Norwegian ancestry from the Tromsø cohort24 were used as controls. The University of 
California, San Diego, Institutional Review Board (Human Research Protection Program) 
exempted the project under 45 CFR 46 subpart A §46.101b, category 4.
Whole-exome sequencing
DNA (2.5 µg) was fragmented to ~175 bp using sonification (Covaris, Woburn, MA), 
fragment ends were repaired, and adaptors including sample index barcodes were ligated. 
The resulting DNA libraries were amplified by six cycles of PCR, 500 ng enriched using 
SUPPLEMENTARY MATERIAL
Supplementary material is linked to the online version of the paper at http://www.nature.com/gim.
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SureSelect Human All v4 kit (Agilent, Santa Clara, CA) to capture 51 Mb of target 
sequence,25 and sequenced (paired-end 100-bp reads) using a Illumina HiSeq 2000 
(Illumina, San Diego, CA) (~100 million reads per sample; ~30× coverage). Reads were 
aligned to the human reference genome (hg19) using Burrows-Wheeler Aligner (BWA)26; 
read pairs identified as duplicates by Picard Mark Duplicates (http://sourceforge.net/
projects/picard/) were removed. Using Genome Analysis Toolkit (GATK),27 reads were 
realigned around insertion/deletion sites and base quality scores were recalibrated. 
Genotypes were called in all 140 samples simultaneously using GATK and filtered using the 
variant quality score recalibration protocol.
Exome sequence data are available through dbGaP accession phs000776. http://
www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000776.v1.p1.
Identity by descent estimation
Identity by descent was estimated using PLINK (v1.07)28 using autosomal single-nucleotide 
polymorphisms (SNPs) with genotyping call rates >0.99, minor allele frequency >5%, and a 
per-sample call rate >80%. Pruning was performed to retain SNPs in linkage equilibrium at 
r2 value < 0.2.
Ancestry estimation
Ancestry was estimated as previously described29 using the reference population of 1,445 
unrelated participants of the 1000 Genomes Project (1KG) comprising five superpopulation 
groups (African, Asian, South Asian, European, and American admixed). Genotypes of 
these individuals on the Illumina Omni 2.5 array (Illumina, San Diego, CA) were 
downloaded (29 August 2012), and variants were linked to dbSNP 135 identifiers using 
GATK (there were 41,572 SNPs shared between the Omni 2.5 array and the exome 
sequencing data set). To identify SNPs informative for ancestry, informativeness (In) was 
calculated across the five superpopulation groups, and markers were chosen in order of In 
that were in low linkage equilibrium (r2 < 0.2) with previously chosen markers within 1 Mb. 
SNPs with positive informativeness (n = 29,973) were used to cluster the genotypes of each 
MCCD case with the 1KG participants using multidimensional scaling in PLINK v1.07. To 
identify the most similar superpopulation for each MCCD case, a linear discriminant model 
was created based on the top 20 multidimensional scaling components using linear 
discriminant analysis (lda command in MASS package30 in R) with the 1KG individuals as 
a training set.
Identification and analysis of runs of homozygosity
We identified long stretches of homozygous DNA (runs of homozygosity (ROHs)) using 
PLINK v1.07 (--homozyg) with a sliding window of 100 SNP length and a minor allele 
frequency criterion of 0.05 across MCCD and Tromsø individuals. The window threshold to 
call ROHs was 250 kb, and default values for the number of heterozygous SNPs (=1) and 
number of missing SNPs (=5) allowed in the ROH were used. To ensure that locally low 
SNP density did not spuriously increase the length of an ROH, PLINK v1.07 default values 
were used with a minimum SNP density of 50 kb and a maximum gap between two 
consecutive SNPs of 1,000 kb. To determine if the numbers of individuals with large ROHs 
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in the three MCCD groups were statistically different, for each individual all regions larger 
than 1,600 kb were summed, and a Wilcoxon rank sum test was used to perform pairwise 
comparisons between groups 1, 2, and 3 and the Norwegian controls.
Identification and annotation of high-impact variants in OMIM genes
Variant Call Format (VCF) files were annotated using SnpEff software31 and only high-
impact (missense, frameshift, or splice site mutations) or moderate-impact (nonsynonomous 
mutations) variants were kept. Variants were further required to satisfy four criteria: (i) in a 
homozygous region ≥1.6 Mb in length; (ii) in a gene with an OMIM entry (http://
omim.org/); (iii) either not present or at a frequency less than 1% in dbSNP (v137); and (iv) 
occurring in the exon or splice site of the OMIM gene according to the UCSC Genome 
Browser mRNA track. For Table 1, gene variants were annotated relative to transcripts 
NM_020166.3 for MCCC1 and NM_022132.4 for MCCC2 using Variant Effect Predictor 
(VEP).32 Gene variants are reported in accordance with the Human Genome Variation 
Society (http://www.hgvs.org/).
RESULTS
Whole-exome sequencing reveals no association between the type of genetic lesion or the 
status of homozygous/compound heterozygous mutations and the severity of clinical 
symptoms
To examine the genetic components underlying the varying clinical phenotypes associated 
with MCCD, we performed whole-exome sequencing identifying 274,496 and 307,935 
variants (single-nucleotide variants and insertion/deletions combined) in the 33 cases and 
108 controls, respectively. We first analyzed the mutational spectrum of the MCCC1 and 
MCCC2 genes in the 33 cases and observed that 15 individuals had mutations in MCCC1 
and 18 in MCCC2 (Table 1). Fifteen cases were homozygous (6 for MCCC1 and 9 for 
MCCC2), and 18 were compound heterozygous (9 for MCCC1 and 9 for MCCC2). We 
observed 35 independent mutations, of which 8 mutations were observed more than once, 
resulting in the following patient pairs sharing a mutation: A5 and S20, A7 and A11; A9 and 
A19, A18 and A21; S8 and S25; S9 and S10; S4 and A5; S15, S22, and A20 (Table 1). Of 
the 35 mutations, 14 are reported in dbSNP (v137) with frequencies <0.0015, which is 
consistent with MCCC1 and MCCC2 null mutations being very rare in the population. For 
one case (A4) we identified a homozygous mutation 4 bp after an intron/exon boundary in 
MCCC1, suggesting this mutation may affect splicing. For seven cases we identified only 
one mutant allele (A13, A14, A18, A23, S9, S10, and S23) and inferred that they were 
compound heterozygotes because all individuals were shown to have enzyme deficiency, 
which is not the case when only a single allele is mutated.33 Consistent with previous 
reports,6,12 there was no apparent association between the type of genetic lesion or the status 
of homozygous or compound heterozygous mutations and the absence or presence/severity 
of clinical symptoms.
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MCCD cases that share the same mutation are likely to have inherited the variant from a 
common ancestor
For the MCCD cases that shared a common mutation, we checked for relatedness to 
determine if the mutations were inherited from a common ancestor. We estimated the 
proportion of the genome shared identically by descent using PLINK (PI_HAT value). We 
did not observe individuals related at the level of second-degree relatives or closer because 
all pairs of individuals were reported as having PI_HAT <0.25. Half of the pairs of 
individuals who shared a mutation had cryptic relatedness: A18 and A21 (MCCC1 c.
1526delC mutation) had a PI_HAT = 0.13, indicating third-degree relatives; S4 and A5 
(MCCC1 c.1155A>C mutation) had a PI_HAT of 0.09, indicating fourth-degree relatives; 
A5 and S20 (MCCC1 c.974T>G mutation) have a PI_HAT of 0.09, indicating fourth-degree 
relatives; A9 and A19 (MCCC1 c.558delA mutation) had a PI_HAT of 0.07, indicating 
fourth-degree relatives; and S22, S15, and A20 (MCCC2 c.517_518insT mutation) had 
pairwise PI_HAT of 0.09 (Supplementary Table S2 online). For the three pairs of MCCD 
cases that shared an MCCC2 mutation but did not have cryptic relatedness, we examined the 
genotypes of 36 SNPs (minor allele frequency >5%) in the 265-kb interval encompassing 
the MCCC2 gene for identity by state (Supplementary Table S3 online). If the mutation had 
been inherited from the same distant relative, one would expect them to share not only the 
variant but also the surrounding chromosomal region. Cases S25 and S8 (MCCC2 c.295G>C 
mutation) had identical genotypes at all 36 SNPs, indicating identity by descent. Cases A7 
and A11 (MCCC2 c.1065A>T mutation) had identical genotypes at 35 of the 36 SNPs, 
indicating identity by descent. S9 and S10 (both compound heterozygotes for MCCC2 c.
1015G>A mutation) had dissimilar genotypes in the proximal part of the interval but had 
three SNPs (spanning 5.5 kb) immediately proximal to the mutation and 21 SNPs (spanning 
~800 Kb) distal to the mutation in which one allele was shared in common, suggesting the 
mutation arose only once in a distant ancestor. Our data demonstrate that MCCD cases that 
share the same mutation are most likely to have inherited the variant from a common 
ancestor.
Genetic ancestry does not seem to be an important determinant of the diverse clinical 
manifestations
To determine whether ethnicity plays a role in the manifestation of different clinical 
phenotypes, we estimated the genetic ancestry of each MCCD case using the 1KG 
superpopulations (see Materials and Methods). We visualized ancestry estimation for all 
cases by plotting the first versus second multidimensional scaling components (Figure 1a) 
and the second versus third components (Figure 1b). We had self-reported ancestry for 11 
individuals and observed high agreement between reported ancestry and clustering with 
expected 1KG superpopulations (Supplementary Table S4 online). Additionally, the seven 
pairs of individuals who inherited the same mutation from a common ancestor had similar 
estimated genetic ancestry. We observed that there are approximately equal numbers of 
asymptomatic (group 1) and symptomatic MCCD individuals (groups 2 and 3) assigned to 
each of the five 1KG superpopulations. Thus, genetic ancestry does not seem to be an 
important determinant of the diverse clinical manifestations observed among individuals 
with MCCD.
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Association of consanguinity with MCCD clinical phenotypes
To examine whether consanguinity is associated with MCCD clinical phenotypes, for each 
case we assessed the amount and characterized the length of autosomal DNA segments that 
were homozygous (runs of homozygosity, ROHs). ROHs are common in human genomes 
and represent segments in which identical haplotypes are inherited from each parent. 
Pemberton et al.34 recently classified ROHs by length: short ROHs, which reflect ancient 
haplotype blocks; intermediate ROHs, which reflect background relatedness attributable to a 
population bottleneck; and large ROHs, attributable to recent parental relatedness. For each 
case, ROHs were categorized into three size classes: short regions (250–500 kb), medium 
regions (500–1,600 kb), and large regions >1,600 kb (Figure 2a). Four (22%) group 1 cases, 
one (20%) group 2 case, and seven (70%) group 3 cases have ROHs at or greater than the 
level anticipated for individuals who are the product of second cousin unions. We performed 
all pairwise comparisons among the three MCCD groups to test whether the groups differed 
by their total length of large ROHs (>1,600 kb) using a Wilcoxon rank sum test (Figure 2b). 
We show that MCCD group 3 has significantly higher levels of homozygosity than MCCD 
group 1 (P = 0.02). Although the data suggest that group 3 has higher median levels of 
homozygosity than group 2 and that group 1 had lower median levels than group 2, the test 
failed to achieve significance (P = 0.13 and P = 0.07, respectively), possibly because of a 
small sample sizes. Recent studies show that ROHs are more common and longer than 
expected in unrelated individuals from outbred populations.35,36 For this reason we analyzed 
the 108 controls (Supplementary Figure S1 online), which revealed that only 5 (5%) of these 
individuals had ROHs at the level consistent with being the product of a second cousin 
union. Comparisons of each MCCD group with the healthy control group using the 
Wilcoxon rank sum test demonstrate that group 2 and group 3 MCCD cases had higher 
median homozygosity than the controls, but only group 3 showed a significant difference (P 
= 0.001). Our results show that group 3 cases are significantly more likely to be inbred 
compared with cases that are asymptomatic and healthy controls.
Rare mutations outside of MCCC genes underlie nonspecific phenotypes of MCCD
We hypothesized that group 3 cases harbor homozygous recessive mutations in disease 
genes other than MCCC1 or MCCC2 that are responsible for their nonspecific clinical 
phenotypes. We performed a genome-wide search for rare homozygous variants in large 
ROHs with predicted high or moderate impact on the function of a gene with an OMIM 
entry. For two patients, we observed novel mutations in disease genes and a striking number 
of the patients’ clinical symptoms matching the symptoms described in the OMIM entry. In 
S9, a 1-bp homozygous deletion results in a premature stop codon in immunoglobulin mu 
binding protein 2 (IGHMBP2) (Table 2). Homozygous mutations in IGHMBP2 are known to 
cause spinal muscular atrophy type 1, which has clinical features matching those of S9 
(Table 3). In S28, we identified a 1-bp homozygous deletion in aldehyde dehydrogenase 7 
family, member A1 (ALDH7A1), which may better explain the reported neonatal seizures 
and medically resistant status epilepticus in this patient. For three patients, we identified rare 
variants (minor allele frequency <0.0015) that result in nonsynonomous substitutions or 
frame-shifts in OMIM disease genes. Although these mutations are in dbSNP, they occur 
less frequently than the CFTR p.Phe508del mutation (rs121909001; minor allele frequency 
Shepard et al. Page 7









~0.015), which is the leading cause of cystic fibrosis. For S17, we observed a homozygous 
nonsynonomous variant in tetratricopeptide repeat domain 37 (TTC37), which may underlie 
the reported frequent watery diarrhea, fatigue, and failure to thrive in this individual. In S8, a 
homozygous nonsynonomous variant in aarF domain containing kinase 3 (ADCK3) may 
explain the reported progressive seizures and developmental delay. Finally, in S26 a 
homozygous variant resulting in a frameshift in solute carrier family 46 (folate transporter), 
member 1 (SLC46A1), may result in the reported dysmyelination and hemiparesis. Thus, for 
50% of the MCCD cases in group 3, we observed a homozygous damaging novel mutation 
or rare variant in a disease gene that likely explains their clinical symptoms independently of 
their mutations in MCCC1 or MCCC2.
DISCUSSION
The recommendation from the American College of Medical Genetics and Genomics to 
include MCCD in the newborn screening core panel37 was based on availability and 
perceived necessity of treatment and good understanding of the natural history of the 
disease. Our study suggests that many of the nonspecific symptoms attributed to MCCD 
may not be caused by mutations in MCC, but rather are caused by mutations in other disease 
genes. Although having multiple rare recessive mutations is unusual, the probability of 
having any rare recessive disease is increased by consanguinity. Thus, it is not unusual that 
patients from consanguineous unions affected with MCCD also appear to be more likely to 
carry other rare mutations. Our results together with findings of other studies9,33,38 suggest 
that the clinical consequences of MCCD may be less pervasive than previously believed, 
and when present may be limited to specific effects of defective leucine catabolism. Further 
studies are needed to assess the value of providing treatment to asymptomatic individuals 
with MCCD who are identified through newborn screening.
Although our results help to explain the difference between MCCD patients with 
nonspecific and specific symptoms, they do not address why there are phenotypic 
differences between asymptomatic MCCD individuals and MCCD patients with specific 
symptoms. The biochemical context of MCC in leucine catabolism might arguably render its 
deficiency particularly likely to escape phenotypic expression. Substrate accumulation 
seems to be well tolerated to very high levels, and excretion of 3-methylcrotonylglycine, 3-
hydroxyisovaleric acid, and 3-hydroxyisovalerylcarnitine is efficient (provided that there is 
no depletion of carnitine). Also, the impact of product limitation may be minimal because 
the product of MCC, 3-methylglutaconylCoA, can be generated by reversal of 3-
methylglutaconyl-CoA hydratase, and the subsequent product, hydroxymethylglutaryl-CoA, 
may be alternatively formed from acetoacetate derived from fatty acid oxidation. Therefore, 
to observe a disease phenotype, it may be that mutations other than those in MCCC1 and 
MCCC2 are needed. Another possibility is that environmental factors (e.g., infection, 
catabolic stress) trigger specific symptoms in some MCCD patients. Further studies using 
cases specifically determined not to be inbred might help resolve the difference between 
asymptomatic MCCD cases and MCCD cases with specific symptoms.
Our study has implications for current undiagnosed disease studies that are attempting to 
correlate phenotypes to specific genotypes through large-scale sequencing. Because 
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individuals from consanguineous unions carry rarer recessive mutations that could cause 
genetic diseases, these individuals may be more likely to be recruited to very rare disease 
studies. For the same reason, they would also be more likely to have phenotypes that could 
be due to multiple loci. Therefore, care must be taken in extrapolating that a mutation that 
explains a portion of the clinical phenotype is causal for the entire complex phenotype. 
Patients with symptoms beyond the usual spectrum of disease for a given disorder should be 
evaluated for other contributing alleles and putative phenotypic modifiers. Additionally, 
inbred individuals are often purposely used to identify disease genes due to the ease of 
mapping autosomal recessive disorders by identifying regions of the genome that are 
homozygous in all affected individuals.39,40 Our results suggest that both genotype–
phenotype correlative sequencing projects and homozygosity mapping studies should take 
into account the level of inbreeding in individuals when attributing the effects of a shared 
mutation on a phenotypically heterogeneous group.
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Figure 1. Genetic clustering of participants in the 1000 Genomes Project and MCCD individuals
One thousand four hundred forty-five unrelated individuals from the 1000 Genomes Project 
and 33 individuals from the MCCD population were clustered on genotype profiles using 
multidimensional scaling (MDS) and plotted according to their final scores on the (a) first 
two dimensions and (b) the second and third dimensions. European (EUR), African (AFR), 
and Asian (ASN) 1000 Genomes Project superpopulation groups are clearly differentiated in 
the first two dimensions, whereas South Asian (SAN) and American admixed (AMR) 
groups are overlapping, reflecting their historical European and Asian ancestry. The 
individuals in the SAN group cluster together. The AMR group is broadly distributed, 
indicating that some individuals are genetically more similar to the EUR group than others 
to either the ASN or AFR groups. In the second and third dimensions, SAN and AMR are 
clearly and distinctly identifiable. MCCD, 3-methylcrotonyl-CoA carboxylase deficiency.
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Figure 2. Comparison of amount and type of ROH for MCCD groups 1, 2, and 3
(a) For each individual, the summed totals of ROHs for the three classes (250–500 kb, 500–
1,600 kb, >1,600 kb) are shown for MCCD individuals organized by symptom group. The 
dashed line indicates the expected amount of homozygosity that would result in the union of 
second cousins. (b) Pairwise P values from the comparison of total ROHs >1,600 kb 
between each MCCD group and Tromsø control group using a Wilcoxon rank sum test. 
Below each group is the median total length of ROH segments >1,600 kb for the individuals 
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in each group. MCCD, 3-methylcrotonyl-CoA carboxylase deficiency; ROH, run of 
homozygosity.
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Table 3
OMIM entry disease descriptions matched with the symptoms of the corresponding MCCD case
Sample Symptomsa
OMIM
number OMIM title Matching terms
S9 Failure to thrive, hypotonia, 
diaphragmatic paresis and brain 
atrophy, progressive respiratory 
insufficiency, fatal at 6.5 months





S17 Failure to thrive at age 7 months, 
frequent watery diarrhea, fatigue
222470 TRICHOHEPATOENTERIC SYNDROME 1; 
THES1
Failure to thrive, frequent 
watery diarrhea
S28 Neonatal seizure onset, 
unresponsive to standard 
anticonvulsants, status epilepticus
107323 EPILEPSY, PYRIDOXINE-DEPENDENT Neonatal seizure onset, 
unresponsive to standard 
anticonvulsants, status 
epilepticus
S8 Developmental delay, muscular 
hypotonia, progressive seizures, 
died from circulatory failure after 
prolonged epileptic seizures




S26 Psychomotor developmental delay, 
encephalopathy at 5 years of age, 
hemiparesis at 13 years of age 
consistent with multiple sclerosis 
course, neutropenia
611672 SOLUTE CARRIER FAMILY 46 (FOLATE 
TRANSPORTER), MEMBER 1
Delayed motor 
development, delay in 
myelination, hemiplegic, 
leukopenia
MCCD, 3-methylcrotonyl-CoA carboxylase deficiency.
aSymptoms as reported by treating physician (references in Table 1).
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